Barriers to effective treatment of vaginal atrophy with local estrogen therapy

Vaginal atrophy is a common condition among postmenopausal women, among whom many exhibit both vulvovaginal symptoms (eg, dryness, irritation, itching, and pain with intercourse) and urinary symptoms (eg, increased frequency, urgency, incontinence, urinary tract infections, and dysuria). Unfortunately, few women with symptoms of vaginal atrophy report seeking treatment from a health care provider. The goal of this article is to examine reasons why patients and health care providers do not engage in discourse regarding this important topic. It is important to initiate conversations with postmenopausal women and counsel them on both why the changes occur and potential treatment options.

[1]  A. Cano,et al.  The therapeutic effect of a new ultra low concentration estriol gel formulation (0.005% estriol vaginal gel) on symptoms and signs of postmenopausal vaginal atrophy: results from a pivotal phase III study , 2012, Menopause.

[2]  Peter J. Schmidt,et al.  The 2022 hormone therapy position statement of The North American Menopause Society , 2022, Menopause.

[3]  N. Panay,et al.  Treatment of postmenopausal vaginal atrophy with 10-µg estradiol vaginal tablets , 2012, Menopause international.

[4]  R. Nappi,et al.  Vaginal Health: Insights, Views & Attitudes (VIVA) – results from an international survey , 2012, Climacteric : the journal of the International Menopause Society.

[5]  J. Angel,et al.  The new health care law: how will women near retirement fare? , 2011, Women's health issues : official publication of the Jacobs Institute of Women's Health.

[6]  M. Andelloux.  Products for sexual lubrication: understanding and addressing options with your patients. , 2011, Nursing for women's health.

[7]  N. Panay,et al.  Recommendations for the management of postmenopausal vaginal atrophy , 2010, Climacteric : the journal of the International Menopause Society.

[8]  R. Nappi,et al.  Women's voices in the menopause: results from an international survey on vaginal atrophy. , 2010, Maturitas.

[9]  R. Gut,et al.  Endometrial Safety of Ultra-Low-Dose Estradiol Vaginal Tablets , 2010, Obstetrics and gynecology.

[10]  C. Stika.  Atrophic vaginitis , 2010, Dermatologic therapy.

[11]  J. Waitzinger,et al.  Minimized estradiol absorption with ultra-low-dose 10 μg 17β-estradiol vaginal tablets , 2010, Climacteric : the journal of the International Menopause Society.

[12]  L. Shuster,et al.  Vulvovaginal atrophy. , 2010, Mayo Clinic proceedings.

[13]  N. Santoro,et al.  Prevalence and impact of vaginal symptoms among postmenopausal women. , 2009, The journal of sexual medicine.

[14]  G. Bachmann,et al.  Efficacy and safety of low-dose regimens of conjugated estrogens cream administered vaginally , 2009, Menopause.

[15]  Amanda J Lee,et al.  Web-based survey on the effect of menopause on women's libido in a computer-literate population , 2009, Menopause international.

[16]  R. Gut,et al.  Effective Treatment of Vaginal Atrophy With an Ultra–Low-Dose Estradiol Vaginal Tablet , 2008, Obstetrics and gynecology.

[17]  Lin Shou-qin,et al.  The role of local vaginal estrogen for treatment of vaginal atrophy in postmenopausal women:2007 position statement of The North American Menopause Society , 2008 .

[18]  P. Goss,et al.  Superiority of gas chromatography/tandem mass spectrometry assay (GC/MS/MS) for estradiol for monitoring of aromatase inhibitor therapy , 2007, Steroids.

[19]  G. Bachmann,et al.  The role of local vaginal estrogen for treatment of vaginal atrophy in postmenopausal women: 2007 position statement of The North American Menopause Society , 2007, Menopause.

[20]  S. Cummings,et al.  Comparison of methods to measure low serum estradiol levels in postmenopausal women. , 2006, The Journal of clinical endocrinology and metabolism.

[21]  S. O'neill,et al.  Endometrial and vaginal effects of low-dose estradiol delivered by vaginal ring or vaginal tablet , 2005, Climacteric : the journal of the International Menopause Society.

[22]  M. Bygdeman,et al.  Replens versus dienoestrol cream in the symptomatic treatment of vaginal atrophy in postmenopausal women. , 1996, Maturitas.

[23]  L. Nachtigall.  Comparative study: Replens versus local estrogen in menopausal women. , 1994, Fertility and sterility.